The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Add-On Voclosporin Improves Outcomes in Lupus Nephritis

Add-On Voclosporin Improves Outcomes in Lupus Nephritis

June 2, 2021 • By David Douglas

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Voclosporin (Lupkynis) in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study.

You Might Also Like
  • FDA Approves Belimumab & Voclosporin for Lupus Nephritis
  • Voclosporin Promising for Lupus Nephritis
  • Renal Transplant Outcomes in Patients with Lupus Nephritis

“Lupus nephritis can be a devastating condition if not diagnosed and managed early. These data establish voclosporin as an efficacious and safe, rapid-acting new treatment option for patients in need,” says Brad H. Rovin, MD,of Ohio State University Wexler Medical Center, Columbus, in a company press release.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Voclosporin, a novel calcineurin inhibitor, was approved in combination with immunosuppressive therapy to treat adults with active lupus nephritis by the U.S. Food and Drug Administration (FDA) in January.

Dr. Rovin and colleagues conducted a double-blind, randomized phase 3 trial involving 357 patients in 27 countries. They were randomized to oral voclosporin (23.7 mg twice daily) or placebo, along with MMF (1 g twice daily) and rapidly tapered low-dose oral steroids.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The primary endpoint of complete renal response at week 52 was achieved in significantly more patients in the voclosporin group (41%) than in the placebo group (23%) giving an odds ratio of 2.65 (P<0.0001).

The proportion of patients achieving a complete renal response at week 24 was also significantly higher in the voclosporin group than the placebo group.

Serious adverse events were seen in 21% of patients in both groups. Six patients died during the study period, five of whom were in the placebo group. None of the deaths were considered to be treatment related.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The most frequent serious adverse event involving infection was pneumonia, seen in seven patients in the active treatment group and in eight patients in the placebo group.

“This study,” Dr. Rovin tells Reuters Health by email, “provides important validation of the benefits of early intervention in lupus nephritis and the potential of this new dedicated treatment option for the lupus nephritis community.”

The ongoing AURORA 2 extension study will provide safety and efficacy data on an additional two years of treatment. “Lupus nephritis is chronic disease and it is important to evaluate the long-term effects of therapeutic interventions in terms of both efficacy and safety,” the researchers write.

Dr. Rovin has received personal fees from Aurinia and a number of authors are employees and holders of company stock.


Reference

  1. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070–2080. Epub 2021 May 7.

 

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Lupus nephritis, voclosporin

You Might Also Like:
  • FDA Approves Belimumab & Voclosporin for Lupus Nephritis
  • Voclosporin Promising for Lupus Nephritis
  • Renal Transplant Outcomes in Patients with Lupus Nephritis
  • Subcutaneous Belimumab Improves Systemic Lupus Srythematosus Outcomes

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)